홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Diisopropylethylamine → (1R,3aS,5aR,5bR,7aR,11aS,13aR,13bR)-9-(4-(isopropylsulfonylcarbamoyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylic acid

HRID 406883
인쇄

반응식

HRID 406883 반응식
[CH3:1][CH:2]([S:4]([NH2:7])(=[O:6])=[O:5])[CH3:3].CCN(C(C)C)C(C)C.Cl[C:18]([C:20]1[CH:25]=[CH:24][C:23]([C:26]2[C:27]([CH3:64])([CH3:63])[C@H:28]3[C@:41]([CH3:44])([CH2:42][CH:43]=2)[CH:40]2[C@:31]([CH3:62])([C@@:32]4([CH3:61])[C@H:37]([CH2:38][CH2:39]2)[C@H:36]2[C@H:45]([C:48]([CH3:50])=[CH2:49])[CH2:46][CH2:47][C@:35]2([C:51]([O:53]CC2C=CC=CC=2)=[O:52])[CH2:34][CH2:33]4)[CH2:30][CH2:29]3)=[CH:22][CH:21]=1)=[O:19]>CN(C1C=CN=CC=1)C.COCCOC>[CH:2]([S:4]([NH:7][C:18]([C:20]1[CH:25]=[CH:24][C:23]([C:26]2[C:27]([CH3:64])([CH3:63])[C@H:28]3[C@:41]([CH3:44])([CH2:42][CH:43]=2)[CH:40]2[C@:31]([CH3:62])([C@@:32]4([CH3:61])[C@H:37]([CH2:38][CH2:39]2)[C@H:36]2[C@H:45]([C:48]([CH3:50])=[CH2:49])[CH2:46][CH2:47][C@:35]2([C:51]([OH:53])=[O:52])[CH2:34][CH2:33]4)[CH2:30][CH2:29]3)=[CH:22][CH:21]=1)=[O:19])(=[O:6])=[O:5])([CH3:3])[CH3:1]
참가 물질실험 절차출처 및 근거반응 노트

참가 물질

6

반응물 3

HCID 81531DiisopropylethylamineHCID 3549191Propane-2-sulfonamideHCID 86666259(1R,3aS,5aR,5bR,7aR,11aS,13aR,13bR)-benzyl 9-(4-(chlorocarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylate

생성물 1

HCID 67774684
(1R,3aS,5aR,5bR,7aR,11aS,13aR,13bR)-9-(4-(isopropylsulfonylcarbamoyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylic acid

시약·촉매·용매 2

HCID 142844-(Dimethylamino)pyridine촉매HCID 80711,2-Dimethoxyethane용매

실험 절차

To a mixture of propane-2-sulfonamide (18.46 mg, 0.150 mmol), DMAP (0.915 mg, 7.49 μmol) and Hunig's Base (0.065 mL, 0.375 mmol) in DME (2 mL) was added (1R,3aS,5aR,5bR,7aR,11aS,13aR,13bR)-benzyl 9-(4-(chlorocarbonyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylate (50 mg, 0.075 mmol). The reaction mixture was stirred for 16 hours. LCMS indicated the formation of the desired product. The reaction mixture was quenched with distilled water, extracted with ethyl acetate and concentrated under reduced pressure to give crude intermediate (1R,3aS,5aR,5bR,7aR,11aS,13aR,13bR)-benzyl 9-(4-(isopropylsulfonylcarbamoyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylate as a yellow solid. LCMS: m/e 754.60 (M+H)+, 2.36 min (method 7). To this intermediate (50 mg, 0.066 mmol) in EtOAc (2 mL) and MeOH (2.00 mL) was added 10% Pd/C (21.17 mg, 0.020 mmol). The reaction mixture was hydrogentated using a Parr shaker at 40 Psi for 17 hours. LCMS indicated the reaction was completed. The reaction mixture was filtered through a pad of celite and concentrated under reduced. The residue was purified by prep HPLC to provide the desired product, (1R,3aS,5aR,5bR,7aR,11aS,13aR,13bR)-9-(4-(isopropylsulfonylcarbamoyl)phenyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysene-3a-carboxylic acid, as a white solid (12 mg, 26%). LCMS: m/e 664.48 (M+H)+, 2.18 min (method 7). 1H NMR (500 MHz, CHLOROFORM-d) δ ppm 0.91 (s, 6H), 0.96 (s, 3H), 1.00 (d, J=4.27 Hz, 6H), 1.18-1.27 (m, 8H), 1.35-1.55 (m, 13H), 1.60-1.75 (m, 5H), 1.94-2.03 (m, 2H), 2.07-2.14 (m, 1H), 2.22-2.31 (m, 2H), 2.97-3.07 (m, 1H), 3.98-4.08 (m, 1H), 4.61 (s, 1H), 4.74 (s, 1H), 5.28 (d, J=4.88 Hz, 1H), 7.23-7.25 (m, 2H), 7.74 (d, J=8.24 Hz, 2H).

출처 및 근거

ORD 기록
ord-cc77223c4dab46a4a9dae5cb37ac5740
출처 데이터셋
uspto-grants-2014_06
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08754068B2

반응 노트

이 페이지에서참가 물질실험 절차출처 및 근거반응 노트